Feature | July 25, 2013

First Robotic-Assisted STEMI Stent Performed at Sanford Aberdeen Medical Center

Interventional cardiologist performs CorPath Robotic angioplasty, door-to-balloon time superior to national average

CorPath Robotic Angioplasty Corindus Sanford Aberdeen Medical Center South Dakot

July 25, 2013 — Sanford Aberdeen Medical Center in Aberdeen, S.D. became the first hospital to perform a robotic angioplasty for a patient with an acute heart attack, achieving a far better door-to-balloon time than the national standard. Interventional cardiologist Puneet Sharma, performed the percutaneous coronary intervention (PCI) to treat a patient that had experienced a heart attack and presented to the Sanford Aberdeen emergency department. Utilizing the U.S. Food and Drug Administration (FDA)-cleared CorPath System, Sharma was able to perform the robotic-assisted angioplasty procedure and restore blood flow to the patient’s heart within 68 minutes of their arrival.

The current nationwide standard for door-to-balloon time — from when a patient with a heart attack is presented to the emergency department (ED) to inflating a balloon in his coronary arteries to restore blood flow to the heart — is 90 minutes. These standards were developed by the American College of Cardiology (ACC) to improve timely access to the cath lab and by that improving clinical outcome.

“Timely access to emergency cardiac care and survival is partly dependent on access to services and technology,” said Sharma. “Being able to perform a CorPath Robotic Angioplasty on a STEMI patient within 68 minutes is a great benefit. As shown with the latest procedure, robotic-assisted angioplasties improve rural access and quality of care as more patients in this area will have access for advanced specialty care. The implementation of the CorPath System and its ability to precisely and rapidly execute an angioplasty procedure with only one stent in the patient heart is a great example of Sanford Health’s commitment to enhanced clinical outcome for our patients.”

The CorPath System is the first and only FDA cleared technology that enables precise, robotic-assisted angioplasties to open arteries and restore blood flow in patients with coronary artery disease. Seated in an interventional cockpit, the interventional cardiologist advances stents and guidewires via a joystick with millimeter-by-millimeter precision. The system, which is quickly being adopted as the new standard of care in coronary angioplasty procedures, may also improve clinical outcomes by enabling precise measurement of the anatomy, which could potentially lead to better stent placements.

Sanford Health performs robotic-assisted angioplasty procedures with the CorPath System at both Sanford Heart Hospital in Sioux Falls and Sanford Aberdeen Medical Center. It is the first and only health system in the region utilizing the CorPath System.

For more information: www.corindus.com

Related Content

Synergy stent, abluminal polymer DES, bioresorbable polymer DES, bioresorbable polymer metallic stent

The Synergy stent is the first FDA cleared drug-eluting stent to use a bioresorbable polymer drug carrier. When the polymer dissolves after about four months, the devices become a bare metal stent. The technology is supposed to reduce the rate of late stent thrombosis due to vessel inflammation caused by durable polymers.

Feature | Stents Bioresorbable| January 17, 2017 | Dave Fornell
One of the big advancements in drug-eluting stent (DES) technology has been the development of bioresorbable polymers
Medtronic, CoreValve Evolut R TAVR system, U.S. IDE Study, TCT 2016
News | Heart Valve Technology| November 03, 2016
Medtronic plc unveiled new clinical data showing that patients treated with the self-expanding CoreValve Evolut R...
congenital heart patients, cardiac cath lab, anesthesia sedation practices, joint document, SCAI, SPA, CCAS
News | Congenital Heart| November 03, 2016
The Society for Cardiovascular Angiography and Interventions (SCAI), the Society for Pediatric Anesthesia (SPA) and the...
open-heart surgery, PCI, percutaneous coronary intervention, NOBLE trial, left main coronary artery disease, LMCAD, TCT 2016
News | Cardiovascular Surgery| November 03, 2016
Coronary artery bypass (CABG) surgery is the standard treatment for revascularization in patients with left main...
SENTINEL trial, transcatheter embolic protection, TCEP, TAVR, stroke, TCT 2016
News | Embolic Protection Devices| November 03, 2016
An international study has found that transcatheter cerebral embolic protection (TCEP) is safe, provides effective...
News | Drug-Eluting Balloons| November 03, 2016
The Spectranetics Corp. announced that it has submitted to the U.S. Food & Drug Administration (FDA) its Pre-Market...
RESPECT trial, Amplatzer PFO Occluder, St. Jude Medical, TCT 2016
News | Structural Heart Occluders| November 02, 2016
St. Jude Medical Inc. announced the long-term data from RESPECT, a landmark trial, during a First Report session at the...
Medtronic, Resolute Integrity DES, drug-eluting stent, BIO-RESORT study, TCT 2016
News | Stents Drug Eluting| November 02, 2016
Investigators recently unveiled clinical data from the independent BIO-RESORT study, representing the first all-comers...
Medtronic, Harmony TPV, transcatheter pulmonary valve, clinical study results, TCT 2016
News | Heart Valve Technology| November 02, 2016
Medtronic plc recently announced new clinical data for the Harmony Transcatheter Pulmonary Valve (TPV) from its early...
St. Jude Medical, Amplatzer PFO Occluder, FDA approval, U.S. launch
Technology | Structural Heart Occluders| November 02, 2016
St. Jude Medical Inc. announced this week the U.S. Food and Drug Administration (FDA) approval and launch of the...
Overlay Init